• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Rhythm Pharma

Rhythm Pharmaceuticals
Biotech

Rhythm installs Shapiro to replace departing CMO

Linda Shapiro Manning landed the role after spending most of the previous decade at Boehringer Ingelheim, Merck and Novo Nordisk.
Nick Paul Taylor Sep 3, 2021 9:59am
AstraZenecas new Cambridge UK RD center and global HQ - 2nd floor

Alexion pays $100M for Rhythm's speedy review voucher

Jan 6, 2021 10:23am
parachute landscape

Biogen CFO Capello steps down from role—Chutes & Ladders

Jul 24, 2020 9:30am
Rhythm Pharmaceuticals CEO David Meeker

Ex-Genzyme boss Meeker hops from KSQ to Rhythm Pharma

Jul 20, 2020 10:15am
FDA Building 2

As Rhythm Pharmaceuticals preps for first approval, CEO exits

Jan 7, 2020 7:50am
Rhythm Pharmaceuticals

Rhythm's genetic obesity drug hits primary endpoint in phase 3

Aug 7, 2019 9:29am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings